CAPTRUST Financial Advisors’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

CAPTRUST Financial Advisors’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-655	Closed	-$14K	–	2248
2022 Q2	$14K	Hold	655	–	–	﹤0.01%	3562
2022 Q1	$18K	Hold	655	–	–	﹤0.01%	3448
2021 Q4	$25K	Hold	655	–	–	﹤0.01%	3131
2021 Q3	$30K	Hold	655	–	–	﹤0.01%	2894
2021 Q2	$33K	Hold	655	–	–	﹤0.01%	2769
2021 Q1	$34K	Hold	655	–	–	﹤0.01%	2668
2020 Q4	$32K	Hold	655	–	–	﹤0.01%	2028
2020 Q3	$26K	Hold	655	–	–	﹤0.01%	1862
2020 Q2	$28K	Buy	+655	New	+$25.1K	﹤0.01%	1813

Other funds holding BBC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

CAPTRUST Financial Advisors's BBC Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q3 2022, closing a stake of 655 shares — an estimated $14K sold.

CAPTRUST Financial Advisors first reported a position in BBC in Q2 2020 and held it in 9 quarters. The position peaked at $34K in Q1 2021. 16 funds tracked by Wall St. Rank hold BBC as of Q3 2022.

CAPTRUST Financial Advisors reported no remaining Virtus Biotech Clinical Trials ETF position as of Q3 2022 after selling out during the quarter.
CAPTRUST Financial Advisors sold 655 Virtus Biotech Clinical Trials ETF shares in Q3 2022, an estimated $14K.
CAPTRUST Financial Advisors first reported a position in Virtus Biotech Clinical Trials ETF in Q2 2020 and held it in 9 quarters.
CAPTRUST Financial Advisors's Virtus Biotech Clinical Trials ETF position peaked at $34K in Q1 2021.
16 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.